Regulatory Show all
July 7 | 2026

Correction: 2cureX AB accelerates reintegration of operating business into the listed company

Read more
July 7 | 2026

Rättelse: 2cureX AB påskyndar återintegreringen av den operativa verksamheten i det noterade bolaget

Read more
July 6 | 2026

2cureX AB påskyndar återintegreringen av den operativa verksamheten i det noterade bolaget

Read more
July 6 | 2026

2cureX AB accelerates reintegration of operating business into the listed company

Read more
June 25 | 2026

The Directed Issue announced 22 April 2026 will be registered at Bolagsverket under the authorization granted by the Annual General Meeting held on 25 June 2026.

Read more
June 25 | 2026

Den riktade emissionen som tillkännagavs den 22 april 2026 kommer att registreras hos Bolagsverket under den bemyndigande som beviljades av årsstämman den 25 juni 2026.

Read more
June 25 | 2026

Kommuniké från årsstämma torsdagen den 25 juni 2026 i 2cureX AB

Read more
June 25 | 2026

Communiqué from the Annual General Meeting on Thursday 25 June 2026 in 2cureX AB

Read more
May 28 | 2026

Publicering av årsredovisningen för 2cureX AB (publ)

Read more
May 28 | 2026

THIS PRESS RELEASE IS AN ENGLISH TRANSLATION OF THE LEGALLY BINDING SWEDISH PRESS RELEASE: “PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (publ)”.

Read more
May 25 | 2026

Correction: Notice of annual general meeting in 2cureX AB

Read more
May 25 | 2026

Rättelse: Kallelse till årsstämma i 2cureX AB

Read more
May 25 | 2026

Notice of annual general meeting in 2cureX AB

Read more
May 25 | 2026

Kallelse till årsstämma i 2cureX AB

Read more
May 20 | 2026

2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor

Read more
May 19 | 2026

2cureX AB’s Executive Management is pleased to invite shareholders and investors to a live webcast and business update on 20 May at 7pm CET.

Read more
April 22 | 2026

2cureX AB completes oversubscribed directed issue

Read more
February 26 | 2026

2cureX AB (publ) publishes Interim Report for the Second Half of 2025

Read more